Calliditas Therapeutics AB (CALT)
20.13
+0.13
(+0.65%)
USD |
NASDAQ |
May 06, 16:00
19.56
-0.57
(-2.83%)
After-Hours: 20:00
Calliditas Therapeutics Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | 57.43M |
| September 30, 2022 | 23.66M |
| June 30, 2022 | 82.32M |
| March 31, 2022 | 58.44M |
| December 31, 2021 | 50.84M |
| September 30, 2021 | 43.34M |
| June 30, 2021 | 2.271M |
| March 31, 2021 | 84.20M |
| December 31, 2020 | 83.95M |
| September 30, 2020 | 95.95M |
| June 30, 2020 | 101.53M |
| Date | Value |
|---|---|
| March 31, 2020 | 19.66M |
| December 31, 2019 | 21.05M |
| September 30, 2019 | 23.58M |
| June 30, 2019 | 79.06M |
| March 31, 2019 | 78.90M |
| December 31, 2018 | 82.56M |
| September 30, 2018 | 86.93M |
| June 30, 2018 | 11.26M |
| March 31, 2018 | 15.52M |
| December 31, 2017 | 11.88M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.271M
Minimum
Jun 2021
101.53M
Maximum
Jun 2020
55.15M
Average
57.43M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
| DBV Technologies SA | 6.767M |
| Cellectis SA | 82.86M |
| Adaptimmune Therapeutics PLC | 0.88M |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals Plc | 12.76M |